ERBB2 and breast carcinoma: Although this review focuses on TNBC, it is important to note that endocrine-resistant luminal breast cancer and trastuzumab-resistant HER2+ breast cancer also exhibit metabolic reprogramming, whereby the glycolysis rate and associated lactate acidosis are increased (17, 171–173).